Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research report released on Saturday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $2.00 price objective on shares of Senseonics in a report on Wednesday, August 14th.

Senseonics Stock Down 2.0 %

Shares of NYSE:SENS opened at $0.36 on Friday. Senseonics has a 52-week low of $0.32 and a 52-week high of $0.75. The company has a market capitalization of $192.86 million, a PE ratio of -2.57 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11. The company has a fifty day moving average of $0.41 and a 200-day moving average of $0.45.

Senseonics (NYSE:SENS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The business had revenue of $4.87 million for the quarter, compared to analyst estimates of $4.86 million. On average, equities analysts predict that Senseonics will post -0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. RPO LLC acquired a new stake in shares of Senseonics in the fourth quarter valued at about $37,000. State Board of Administration of Florida Retirement System bought a new position in Senseonics during the 1st quarter worth approximately $91,000. Virtu Financial LLC acquired a new position in shares of Senseonics in the 1st quarter worth approximately $162,000. Cubist Systematic Strategies LLC boosted its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Senseonics by 16.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the last quarter. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.